| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5051 | Tc-aqp1-1 | Aquaporin 1 (AQP1) channel blocker |
|
| DCC5052 | tc-c-14g | Potent CB1 receptor inverse agonist |
|
| DCC5053 | Tc-e 5006 | Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels |
|
| DCC5054 | FPR Agonist 43 Featured | FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist. |
|
| DCC5055 | Tc-g1004 | Potent and selective antagonist of adenosine A2A receptors |
|
| DCC5056 | Tch-013 | Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines |
|
| DCC5057 | Tc-i 2000 Featured | Novel TRPM8 channel blocker |
|
| DCC5058 | Tc-i 2014 | Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models |
|
| DCC5059 | tcmdc-125802 | Antimalarial; Novel inhibitor of HepG2 |
|
| DCC5060 | Tcmdc-135051 Tfa Salt | Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga |
|
| DCC5061 | Tcn-237 Dihydrochloride | Highly potent NR2B-selective NMDA receptor antagonist |
|
| DCC5062 | Tc-ot-39 | Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors |
|
| DCC5063 | Tc-s 7005 | Potent and selective polo-like kinase 2 (PLK2) inhibitor |
|
| DCC5064 | Tcs2312 | Novel potent and selective CHK1 kinase inhibitor |
|
| DCC5065 | Tcs2314 Featured | Novel Integrin very late antigen-4 (VLA-4; α4β1) antagonist, blocking the activation of inflammatory cells. |
|
| DCC5066 | Tcs-3035 | Novel GPR35 agonist |
|
| DCC5067 | Tcs-401 | Insulin receptor sensitizing agent; Selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) |
|
| DCC5068 | Tc-t 6000 | Potent equilibrative nucleoside transporter 4 (ENT4) inhibitor |
|
| DCC5069 | T-cupm | Sorafenib analogue, retaining cytotoxicity similar to sorafenib in various human cancer cell lines and strongly inhibiting growth in the NCI-60 cell line panel |
|
| DCC5070 | Td-004 | Novel degrader of the anaplastic lymphoma kinase (ALK) fusion protein, effectively inducing ALK degradation and inhibiting the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122, significantly reducing the tumor growth in H3122 xenograft model |
|
| DCC5071 | Td-106 | Novel IKZF1/3 degrader, inhibiting the proliferation of multiple myeloma cells in vitro as well as in vivo |
|
| DCC5072 | Td-1211 | Novel selective opioid receptor antagonist at all three receptor types |
|
| DCC5073 | Td-428 | Novel potent BET protein degrader, inhibiting cell proliferation due to suppressed C-MYC transcription |
|
| DCC5074 | Td-5471 Hydrochloride | Novel long-acting β 2 -adrenoceptor agonist |
|
| DCC5075 | Tdcipp | Hepatotoxicity inducer, significantly up-regulating the expression of genes involved in endoplasmic reticulum stress and Toll-like receptor (TLR) pathway |
|
| DCC5076 | Tdmq20 | Novel Specific Copper Chelator, Reducing Memory Impairments in Alzheimer's Disease Mouse Models |
|
| DCC5077 | Tdp1-in-9a | Novel potent inhibitor of tyrosyl-DNA phosphodiesterase 1 (Tdp1) |
|
| DCC5078 | Tdp222669 | Novel inhibitor of the p53-Hdm2 protein-protein interaction, dose-dependently stabilized P53 and increased P21 and MDM2 expression in JAR choriocarcinoma cells, inducing the p53 regulated gene (PIG-3) and caspase activity |
|
| DCC5079 | Tdr32570 | Novel antimalarial agent |
|
| DCC5080 | Tecovirimat Hydrate Featured | Novel inhibitor of viral p37, blocking the ability of virus particles to be released from infected cells, being used for the treatment of smallpox, monkeypox, orthopoxvirus, and orthopoxviral Disease. |
|
